M&T Bank Corp Sells 329 Shares of Natera, Inc. (NASDAQ:NTRA)

M&T Bank Corp lessened its position in Natera, Inc. (NASDAQ:NTRA) by 4.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,704 shares of the medical research company’s stock after selling 329 shares during the period. M&T Bank Corp’s holdings in Natera were worth $947,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. LRI Investments LLC bought a new position in shares of Natera in the 4th quarter valued at about $29,000. Rakuten Securities Inc. grew its position in shares of Natera by 117.8% in the 1st quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 119 shares during the period. ORG Partners LLC bought a new position in shares of Natera in the 1st quarter valued at about $32,000. EverSource Wealth Advisors LLC grew its position in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the period. Finally, Steward Partners Investment Advisory LLC boosted its holdings in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after buying an additional 332 shares during the period. Institutional investors own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several research analyst reports. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Barclays lifted their target price on shares of Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, May 9th. Piper Sandler lifted their target price on shares of Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a report on Thursday, May 15th. Finally, Wall Street Zen downgraded shares of Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $184.63.

Natera Stock Down 1.4%

Shares of Natera stock opened at $158.18 on Tuesday. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00. The company has a 50-day simple moving average of $161.05 and a two-hundred day simple moving average of $158.41. The stock has a market capitalization of $21.60 billion, a price-to-earnings ratio of -107.60 and a beta of 1.73.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business’s revenue was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.56) EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Solomon Moshkevich sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $157.07, for a total value of $471,210.00. Following the completion of the transaction, the insider directly owned 133,205 shares in the company, valued at approximately $20,922,509.35. The trade was a 2.20% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 4,299 shares of the business’s stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the transaction, the director owned 8,118 shares of the company’s stock, valued at $1,358,628.48. The trade was a 34.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,272 shares of company stock worth $8,345,368. 7.60% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.